Expression of TIM-3 on Lymphocytes in Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its role in immunosuppression during sepsis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis

NCT02180009

Sepsis Severe Sepsis Septic Shock

COMPLETED

Detection Of Monocytes/Macrophages Function And Tim-3 Expression In Septic Patients

NCT01801839

Sepsis SIRS(Systemic Inflammatory Response Syndrome)

COMPLETED

Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis

NCT05126537

28 Day Mortality

UNKNOWN

Comparison the Value of Several Biomarkers of Sepsis

NCT01388725

Systemic Inflammatory Response Syndrome Sepsis

COMPLETED

Dynamic Alterations of Th2/Th1 With New Onset of Community-acquired Severe Sepsis Patients

NCT02883218

Sepsis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immunosuppression is the leading cause of death in septic patients.Lymphocyte apoptosis has been recognized as an important step in the pathogenesis of sepsis. Previous studies indicated that T cell immunoglobulin and mucin protein 3 (TIM-3) is a type I cell surface protein and was identified as a marker of lymphocyte dysfunction. The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its further role in immunosuppression during sepsis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Immunosuppression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Severe sepsis

Patients with severe sepsis

No interventions assigned to this group

SIRS patient

Patients after elective surgeries presented with SIRS but without sepsis

No interventions assigned to this group

Volunteer

Volunteers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with severe sepsis
* patients undergo invasive spine surgery
* healthy volunteers

Exclusion Criteria

* patients with immunodeficient diseases
* patients who accept glucocorticoid or immunosuppressant
* patients with an age older than 18 years
* patients providing the informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes